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Abstract
Objectives: The presence of and the causative role of high-risk human papilloma
virus (HPV) is a subject of controversy in oral squamous cell carcinoma (OSCC). The
disagreement can be related to the misclassification of OSCC as oropharyngeal squa-
mous cell carcinoma and/or lack of standard detection methods. This study aimed to
examine the presence of transcriptionally active high-risk HPV in a homogenous Nor-
wegian cohort of primary and second primary OSCC of the mobile tongue (oral
tongue squamous cell carcinoma—OTSCC).
Methods: Tissue microarrays containing formalin-fixed and paraffin-embedded cores
of 146 OTSCC from the anterior 2/3 of the tongue (n = 128 primary and
n = 18 second primary) from a multicentric Norwegian cohort were examined for the
presence of high-risk HPV by DNA- and RNA-in situ hybridization (ISH) assays and
p16 immunohistochemistry.
Results: Transcriptionally active HPV (E6/E7 mRNA) was not identified in any of the
OTSCC specimens. In parallel, no tumors were positive for HPV by DNA ISH.
Although, 61 (42%) OTSCC demonstrated p16 positivity with varying staining inten-
sity and subcellular localization, only two cases demonstrated strong and uniform
p16-staining (both cytoplasmic and nuclear) in >70% of cancer cells. The absence of
transcriptionally active high-risk HPV in this cohort of OTSCC indicates that high-risk
HPV is an unlikely causative factor in the present material.
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cancer of head and neck, cancer of the mouth, human papilloma virus, immunohistochemistry,
in situ hybridization, squamous cell carcinoma
1 | INTRODUCTION
The oral cavity is considered to be a separate anatomical location
from the oropharynx. Here, squamous cell carcinoma (SCC) accounts
for the majority of malignant tumors (Markopoulos, 2012). The 5-year
overall survival for oral squamous cell carcinoma (OSCC) is about 64%
and is closely related to the tumor stage (Zanoni et al., 2019). In a
recent systematic review, the mobile tongue is shown to be the most
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common site of oral cancer among the patients below 45 years of age
(Hussein et al., 2017). This is of great concern since patients with oral
tongue squamous cell carcinoma (OTSCC) have a significantly more
unfavorable prognosis than those at other oral cavity sites
(Rusthoven, Ballonoff, Raben, & Chen, 2008).
High-risk human papilloma virus (HPV) is the primary etiological
factor in oropharyngeal squamous cell carcinoma (OPSCC) in the
Western world (Vokes, Agrawal, & Seiwert, 2015). Accordingly,
high-risk HPV subtypes have been shown to be present in more
than 70% of OPSCC (Fossum, Lie, Jebsen, Sandlie, & Mork, 2017).
The HPV positive OPSCC is considered to be a biologically distinct
entity and is associated with a higher survival rate as compared to
the conventional HPV negative (tobacco-induced) OPSCC (Ang
et al., 2010). In 1983, Sÿrjanen proposed that HPV could be a possi-
ble etiological factor for a subgroup of OSCC (Syrjänen, Syrjänen,
Lamberg, Pyrhönen, & Nuutinen, 1983). Since then, several studies
have focused on HPV detection in OSCC, however, with conflicting
results (Lewis Jr et al., 2012; Yete, D'Souza, & Saranath, 2018).
Firstly, misclassification of OPSCC as OSCC makes it difficult to ana-
lyze the results (Mirghani, Amen, Moreau, & Lacau St Guily, 2015).
Secondly, lack of standard methodological approach for HPV testing
can significantly lead to over- or underestimation of HPV positivity
(Braakhuis, Brakenhoff, Meijer, Snijders, & Leemans, 2009; Lewis Jr
et al., 2012; Westra, 2014). In a systematic literature review of
approximately 4,000 oral cavity cancer specimens, the weighted
prevalence of polymerase chain reaction (PCR)-based HPV DNA
detection was found to be 20.2% (Isayeva, Li, D, & Brandwein-
Gensler, 2012). However, the high sensitivity of DNA PCR analysis
increases the risk of false positive results. Moreover, HPV DNA
detection does not distinguish an active (driver) HPV infection from
passenger/bystander infection (Kim, Lewis Jr., & Chen, 2018; Madri-
gal, Bishop, & Faquin, 2018). In recent years, the mRNA E6/E7 in situ
hybridization (ISH) technique has become increasing popular and it
allows direct visualization of viral transcripts in routinely processed
tissues, thereby reflecting the active HPV infection (Wang
et al., 2014). To our knowledge, only a few studies using relatively
limited numbers of OSCC have evaluated the presence of high-risk
HPV in OSCC by this technique (Bishop et al., 2012; Lewis Jr
et al., 2012; Poling et al., 2014). Their results indicate that high-risk
HPV prevalence is very low in OSCC and challenge the view that
HPV is a possible etiological factor in OSCC. This underscores the
importance of studies aimed at identifying active HPV infection in a
large and homogenous OSCC cohort.
The current work represents a sub-study of a joint initiative
(Norwegian Oral Cancer [NOROC] multicenter study) between the
four University hospitals in Norway treating OSCC (Bjerkli
et al., 2020). Here, 146 OTSCC diagnosed in Norway from 2005 until
2010 were included. The hypothesis of the current study was that
high-risk HPV infection is uncommon in OTSCC in the Norwegian
population. Here, we compared three different and independent
approaches for high-risk HPV detection (E6/E7 mRNA and DNA ISH
and p16 IHC) in OTSCC.
2 | MATERIAL AND METHODS
2.1 | OTSCC selection and extraction of
clinical data
The study was approved by the Northern Norwegian Regional Com-
mittee for Medical Research Ethics (REK Nord; 2013/1786 and
2015/1381). In this multicenter study, all conventional OSCC cases
diagnosed between January 1, 2005 and December 31, 2009 at the
four Norwegian university hospitals treating head and neck cancer
(Oslo, Bergen, Trondheim, and Tromsø) were retrospectively identi-
fied. Using ICD-10 codes (C02-C06) except for codes C05.1 and
C05.2 (oropharyngeal sites, and cancer of the external upper or lower
lip/vermilion), a total of 608 OSCC patients were identified from the
electronic health record. Two hundred and seventy-three OTSCC with
clinical data were identified. Of the 273 OTSCC, 146 (128 primary
+ 18 second primary) were included in this study (for details of the
exclusion criteria, see Figure 1). Unidentifiable clinical data were
recorded in a web-based case report form (CRF). relevant patient data,
ICD-10 diagnosis, TNM classification, treatment received, and mini-
mum of 5 years follow-up (last follow-up date June 1, 2015) were reg-
istered. The patients were classified according to TNM 5th Edition
2005 UICC (Wittekind, Greene, Hutter, Klimpfinger, & Sobin, 2005).
2.2 | Tissue microarray generation
Tissue microarrays were constructed from formalin-fixed, paraffin-
embedded (FFPE) tissue blocks in a fully automated tissue microarray
machine (TMA Master II, 3DHISTECH). Two to four tissue cores (both
invasive front and more superficial parts of the tumors) with a diame-
ter of 2 mm were arrayed on the recipient paraffin blocks. The stained
TMA-sections were scanned (Pannoramic® MIDI scanner, Thermo
Fisher Scientific) and evaluated using the CaseViewer™ software
F IGURE 1 Flowchart illustrating the selection procedure for
OTSCC used in this study. OSCC, oral squamous cell carcinoma;
OTSCC, oral tongue squamous cell carcinoma; RT, radiation therapy;
TMA, tissue microarray
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(3dhistech.com). For scanned images with inadequate focus, the origi-
nal glass slides were examined by a Leitz Aristoplan microscope.
2.3 | p16 immunohistochemistry and scoring
Immunohistochemistry (IHC) was performed on TMAs on a Ventana
Benchmark Ultra automated immunostainer (Ventana Medical Sys-
tems, VMS, Tucson, Arizona), using a mouse monoclonal antibody
clone E6H4 (CINtec® p16 Histology, VMS #805-4713). Bound anti-
body was detected by the biotin-free ultraView Universal DAB Detec-
tion Kit (VMS #760-500). A known p16-expressing OPSCC was used
as a positive control. Sections incubated with phosphate buffer saline
(instead of primary antibody) and with isotype-matched control
(Mouse IgG2a, Sigma-Aldrich, St. Louis, Missouri, # M9144) were used
as negative controls. For details, see Appendix S1. Blinded for the clin-
icopathological data, the p16-stained TMA-sections were scored by
TMS, DS, PJ, and HL. p16 expression was evaluated as follows: Score
0: no expression, Score 1: positive staining in <70% of the tumor cells,
Score 2: positive staining, either nuclear or cytoplasmic in >70% of
the tumor cells, Score 3: Strong and uniform p16-staining (both cyto-
plasmic and nuclear) in >70% of cancer cells (Danish-Head-and-Neck-
Cancer-Group, 2012).
2.4 | HPV DNA ISH and scoring
Automated in situ hybridizations were carried out on TMAs on a Discov-
ery XT (VMS) instrument using Research ISH UltraMap XT procedure and
Ventana products (INFORM HPV III Family 16 Probe (B), #800-4295).
For details, see Appendix S2. Each TMA slide contained HeLa cells as pos-
itive staining controls. Additionally, sections of a known HPV positive
OPSCC were also used as positive controls. A no probe control containing
only RiboHybe and RiboWash served as a negative control.
Blinded for the clinicopathological data, the HPV DNA ISH results
were scored by TMS and DS. The in situ results were interpreted fol-
lowing the manufacturer's guidelines (Interpretation Guide for Ven-
tana INFORM HPV Probes ISH). Any blue nuclear dots in the tumor
cells were regarded as positive staining and all of the samples were
classified binary as either positive or negative.
2.5 | HPV RNA ISH
Automated RNA in situ hybridizations were carried out on a Discov-
ery Ultra (Ventana Medical Systems, Tucson, Arizona) using the fully
automated RNAscope VS HRP assay (#323200 Advanced Cell Diag-
nostics Inc, Hayward, California). Standard protocols were used for
the deparaffinization followed by heat pretreatement using Discovery
CC1 and mRNA sample prep protease treatment. For details, see
Appendix S3. The RNA quality was controlled in some randomly
selected specimens using a probe for the common housekeeping gene
PPIB (#313909 ACD). Background signal was investigated with a
negative control probe for the bacterial gene DapB (#312039 ACD).
Both probes were incubated on full FFPE sections and evaluated
according to the manufactures instructions. Sections of FFPE pellets
of HeLa cells were used as positive controls.
Blinded for the clinicopathological data, the HPV RNA ISH results
were scored by TMS and DS. A positive HPV test result was defined as
punctate staining that localized in the cytoplasm and/or nucleus of malig-
nant cells. The RNA ISH staining was scored according to advanced CELL
diagnostics guidelines, as described in the Appendix S4.
2.6 | Statistical analysis
Descriptive statistics (range, mean, median, and frequencies), where
applicable, were calculated for continuous and categorical variables
using the Statistical Package for the Social Sciences (spss) 26.0 for
Windows (SPSS, Inc., Chicago, Illinois).
TABLE 1 Clinicopathological variables in 128 patients with
primary oral tongue squamous cell carcinoma
Gender Patients (n = 128) (%)
Male 77 (60.2)
Female 51 (39.8)




Never smoker 30 (23.4)
Former smoker 28 (21.9)
Current smoker 56 (43.8)
Unknown 14 (10.9)
Alcohol consumption
Never drinker 12 (9.4)
Seldom (≤1 times weekly) 26 (20.3)
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F IGURE 2 p16
immunohistochemistry in OTSCC.
2A = Strong and uniform p16-staining
(both cytoplasmic and nuclear) in >70%
of OTSCC cells, score
3. 2B = cytoplasmic p16 staining in
>70% of the OTSCC cells, score
2. 2C = weak cytoplasmic staining in
OTSCC cells, score 1. 2D = p16 negative
OTSCC cells, score 0
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3 | RESULTS
This study adheres to the REMARK criteria (McShane et al., 2005).
Out of 146 OTSCC, cases with missing tissue cores or containing
few/no malignant cells in the array were excluded from the analysis.
Following these criteria, two primary cases were excluded from the
analysis of p16 and DNA ISH, and three primary cases were omitted
from the analysis of the RNA ISH.
The clinicopathological variables for 128 primary OTSCC are sum-
marized in Table 1. In brief, primary OTSCC occurred in 77 males
(60.2%) and in 51 females (39.8%). At the time of diagnosis, the
median age for the cohort was 65.5 years (range: 25–90 years). The
second primary OTSCC occurred in 10 males (55.6%) and 8 females
(44.4%). The median age was 72.0 years (range: 42–91 years). Fifteen
tumors (83.3%) were cT1/cT2, two were cT3/cT4 (11.1%) while T-
classification was missing for one case.
3.1 | p16 immunohistochemistry
Sixty-one (42%) OTSCC showed p16 positivity with varying
staining intensity and subcellular localization (Figure 2). Among the
positives, only two (1%) OTSCC (both primary) demonstrated
strong and uniform p16 staining, fulfilling the criteria for Score
3 (Figure 2a). For details on distribution of p16 staining in OTSCC,
see Table 2.
3.2 | HPV DNA ISH
Based on the evaluation criteria described above, all tumors tested
negative for HPV DNA (Figure 3a), including the two cases with p16
Score 3. The positive controls, a known HPV positive OPSCC
(Figure 3b) and HeLa cells (Figure 3c) showed positive staining. The
no probe control was negative (Figure 3d).
3.3 | HPV RNA ISH
No staining or less than one dot to every 10 cells was observed in all
of the OTSCC investigated (Figure 4a). The bacterial gene dapB was
used as negative control (Figure 4b). The positive control, HeLa cells,
was positive (Figure 4c) and the RNA controls with PPIB probes were
positive in two OTSCC (Figure 4d,e).
4 | DISCUSSION
The pathogenic role of HPV in OPSCC has been well established how-
ever, its role in OSCC carcinogenesis is a subject of a controversy.
Although several tests are available for HPV detection, there is no
consensus on the test method(s) for routine diagnostics of HPV-
related oropharyngeal squamous cell carcinomas/head and neck carci-
nomas (Kim et al., 2018). Different methods have different detection
TABLE 2 Results of p16 immunohistochemical staining of 144 OTSCC
p16 IHC staining Number (%) Primary OTSCC number Second primary OTSCC number
Score 0: No expression 83 (58) 72 11
Score 1: Positive staining in <70% of the tumor cells 47 (33) 42 5
Score 2: Positive staining, either nuclear or
cytoplasmic in >70% of the tumor cells
12 (8) 10 2
Score 3: Strong and uniform p16-staining (both
cytoplasmic and nuclear) in >70% of cancer cells
2 (1) 2 0
F IGURE 3 3A = HPV DNA negative OTSCC. 3B = HPV DNA positive OPSCC (positive control). 3C = HPV DNA positive HeLa cells (positive
control). 3D = negative no probe control (in situ without probe) in HeLa cells. OPSCC, oropharyngeal squamous cell carcinoma
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targets including HPV DNA, RNA, viral oncoproteins like E6/E7, cellu-
lar proteins (e.g., p16 protein), or HPV-specific serum antibodies.
Careful selection of the detection technique and viral target is
extremely important to obtain reliable and clinically meaningful data.
However, the commonly used assays such as p16 IHC and PCR have
limitations. For example, p16 overexpression may be caused by
molecular mechanisms independent of the presence of high-risk HPV.
DNA or RNA extraction procedures in PCR techniques destroy the
tumor tissue context of importance for morphological correlation
(Wang et al., 2014). Furthermore, the detection of HPV DNA (either
PCR-based or by ISH) cannot discern an incidental virus from a persis-
tent viral oncogene expression (Westra, 2014). In contrast, RNA ISH
probes complementary to E6/E7 mRNA permit direct visualization of
viral transcripts in routinely processed tissues (Ang et al., 2010; Wang
et al., 2014). Unfortunately, only a handful of studies have used this
approach to examine the HPV infection in OSCC. The current study
consisted of a homogenous and a relatively large number of OTSCC
specimens (both primary and second primary). Use of three different
test methods enabled us to examine the presence of HPV DNA, its
transcriptional active form (E6/E7 mRNA) and the HPV-surrogate
marker, p16.
All of the OTSCC specimens in the current Norwegian cohort
were negative for E6/E7 mRNA and HPV DNA. This is in line with the
observations reported by Lewis et al., where all of the 45 OSCC exam-
ined were negative for HPV E6/E7 RNA (Lewis Jr et al., 2012). Simi-
larly, only one of 107 OSCC contained transcriptionally active HPV in
the study by Bishop et al. (2012). One can suspect that the negative
results with RNA/DNA ISH could be related to overfixation of speci-
mens. However, it has been suggested that the excessive cross-linking
related to overfixation could be partially reversed by protease enzyme
digestion, as done in the current study. Traditionally, DNA/RNA ISH
are considered to have a lower sensitivity, especially in cases with low
abundance of the target nucleic acids, as compared to the PCR-based
methods. However, a recent study has demonstrated a better sensi-
tivity and specificity of ISH techniques as compared to PCR in
formalin-fixed paraffin-embedded OPSCC specimens (Randén-Brady
et al., 2019). Interestingly, the specimens used in that study were col-
lected in the same period of time as in the current study.
Due to the absence of HPV E6/E7 RNA positive carcinomas, we
could not characterize their biological or clinical significance. The pre-
sent HPV DNA results are in agreement with Jaber, Fatani, and
Aldhahri (2019). Lewis et al. identified only one HPV DNA positive
F IGURE 4 Representative figures for high-risk HPV RNA in situ hybridization in oral tongue squamous cell carcinoma (OTSCC). 4A = No
staining or less than one dot to every 10 cells in a HPV mRNA negative OTSCC. 4B = The bacterial gene dapB was used as negative control.
4C = HPV mRNA positive HeLa cells. 4D and E = Two different OTSCC with PPIB probes were positive (RNA control)
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OSCC out of 45 in their study (Lewis Jr et al., 2012). In contrast, a
recent systematic review and meta-analysis reported a higher preva-
lence of HPV DNA positivity in South and Central America and Asia,
as compared to that in North America and Europe (Ndiaye
et al., 2014).
In line with the DNA/RNA ISH results, only two OTSCC were
p16 positive (Score 3). However, both of the p16 positive OTSCC
were negative for HPV DNA and RNA ISH. This suggests that the p16
expression in those cases might be related to non-HPV mechanisms
and supports the view that p16 is not a reliable surrogate marker for
HPV in OTSCC (Bishop et al., 2012; Muller, 2017). A recent meta-
analysis showed that 6.7% of p16 positive head and neck squamous
cell carcinomas were not related to transcriptionally active HPV infec-
tion and that p16 IHC as a single test does not fulfill the criterion to
distinguish between bystander HPV and truly HPV-driven cancers
(Albers, Qian, Kaufmann, & Coordes, 2017).
Although we aimed to investigate conventional OSCC, two non-
keratinizating carcinomas were also included in the current material.
One of the two OTSCC with p16 Score 3 staining was a basaloid car-
cinoma (non-keratinizating). This is an interesting observation since
p16 positive OPSCC usually are non-keratinizing. However, another
non-keratinizing carcinoma included in this study was p16 negative.
A general increase in the incidence of OTSCC has been reported
globally with a shifting trend toward female and/or younger patients
with OTSCC (Ng, Iyer, Tan, & Edgren, 2017). In this study, such a
trend was not obvious in Norway in the period 2005–2010. Here, the
majority of the patients were males and 66% of the patients were
60 years or older. The current study benefitted from the use of a
homogenous cohort of OSCC only including carcinomas from the
anterior 2/3rd of the tongue. As the Norwegian population is homo-
geneous regarding ethnic origin, lifestyle, and OSCC-related risk
habits, the carcinomas can be considered similar with respect to etiol-
ogy and biology, thereby minimizing the potential biases.
Additionally, to minimize the possible bias caused by tumor het-
erogeneity, tissue cores representing both the invasive front and the
more superficial parts of each tumor were included in the TMA block.
From the majority of the OTSCC, four tissue cores were prepared.
From the rest of the tumors, two tissue cores were made. Four cores
should achieve a high degree of concordance when comparing results
from whole sections with those of TMA cores (Goethals et al., 2006).
A high concordance using triplicate TMA cores (Gulmann &
O'Grady, 2003) and even when including only two cores is reported
(Camp, Charette, & Rimm, 2000).
5 | CONCLUSION
None of the 146 OTSCC (128 primary and 18 second primary) diag-
nosed from 2005 until 2010 were found to be positive for high-risk
HPV. In parallel, only two OTSCC were p16 (Score 3) positive. Our
results suggest that high-risk HPV is an unlikely causative factor in the
present material and will not influence future biomarker studies utiliz-
ing the current material.
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